Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
86 studies found for:    "Familial Mediterranean fever"
Show Display Options
Rank Status Study
21 Completed Rilonacept for Deficiency of the Interleukin-1 Receptor Antagonist (DIRA)
Condition: DIRA
Intervention: Drug: Rilonacept
22 Recruiting Observational Study of the Genetic Architecture of Neutrophil-Mediated Inflammatory Skin Diseases
Conditions: Other Specified Inflammatory Disorders of Skin or Subcutaneous Tissue;   Pyoderma Gangrenosum;   Erosive Pustular Dermatosis of the Scalp;   Sweet's Syndrome;   Behcet's Disease;   Bowel-associated Dermatosis-arthritis Syndrome;   Pustular Psoriasis;   Acute Generalized Exanthematous Pustulosis;   Keratoderma Blenorrhagicum;   Sneddon-Wilkinson Disease;   IgA Pemphigus;   Amicrobial Pustulosis of the Folds;   Infantile Acropustulosis;   Transient Neonatal Pustulosis;   Neutrophilic Eccrine Hidradenitis;   Rheumatoid Neutrophilic Dermatitis;   Neutrophilic Urticaria;   Still's Disease;   Erythema Marginatum;   Unclassified Periodic Fever Syndromes / Autoinflammatory Syndromes;   Dermatitis Herpetiformis;   Linear IgA Bullous Dermatosis;   Bullous Systemic Lupus Erythematosus;   Inflammatory Epidermolysis Bullosa Aquisita;   Neutrophilic Dermatosis of the Dorsal Hands (Pustular Vasculitis);   Small Vessel Vasculitis Including Urticarial Vasculitis;   Erythema Elevatum Diutinum;   Medium Vessel Vasculitis
Intervention: Procedure: Collection of biological samples
23 Completed
Has Results
Efficacy and Safety Study of ACZ885 in Patients With Active Recurrent or Chronic TNF-receptor Associated Periodic Syndrome (TRAPS).
Condition: TNF-receptor Associated Periodic Syndromes (TRAPS)
Intervention: Drug: ACZ885
24 Completed Study of the Safety and Efficacy of NC-503 in Secondary (AA) Amyloidosis
Conditions: Secondary (AA) Amyloidosis;   Rheumatoid Arthritis;   Nephrotic Syndrome;   Familial Mediterranean Syndrome;   Kidney Diseases;   Gastrointestinal Diseases
Intervention: Drug: NC-503 (Anti-amyloidotic (AA) Agent)
25 Recruiting Natural History, Pathogenesis, and Outcome of Autoinflammatory Diseases (NOMID/CAPS, DIRA, CANDLE, SAVI, NLRC4-MAS, Still'S-like Diseases, and Other Undifferentiated Autoinflammatory Diseases)
Conditions: NOMID;   CAPS;   DIRA;   NLRC4-MAS;   SAVI;   Other Undifferentiated Autoinflammatory Diseases;   CANDLE
Intervention:
26 Recruiting Kineret CAPS Post Authorisation Study
Condition: Cryopyrin-Associated Periodic Syndromes
Intervention: Drug: anakinra (Kineret)
27 Not yet recruiting Progression of Renal Amyloidosis of FMF and Relation to Serum SAA Level
Condition: Observational
Intervention:
28 Not yet recruiting Efficacy and Safety of Ojeok-san on Korean Patients With Cold Hypersensitivity in the Hands and Feet
Condition: Cold Hypersensitivity
Interventions: Drug: Ojeok-San;   Drug: Placebo
29 Recruiting Efficacy and Safety of Danggui-Sayuk-Ga-Osuyu-Saenggang-tang on Korean Patients With Cold Hypersensitivity in the Hands
Condition: Cold Hypersensitivity
Interventions: Drug: Danggui-Sayuk-Ga-Osuyu-Saenggang-tang;   Drug: Placebo: corn starch
30 Completed Effect of Korean Red Ginseng on Women With Cold Hypersensitivity of Hands and Feet
Condition: Cold Hypersensitivity
Interventions: Drug: Korean red ginseng;   Drug: Placebo
31 Recruiting Phenomics in Autoimmune and Inflammatory Diseases
Conditions: Healthy Volunteer;   Rheumatoid Arthritis;   Ankylosing Spondylitis;   Systemic Lupus Erythematosus/Antiphospholipid Syndrome;   FMF;   Cryopyrin-Associated Periodic Syndromes /TNF-receptor Associated Periodic Syndrome;   Vasculitis;   Uveitis;   Myositis;   Crohn's Disease;   Ulcerative Rectocolitis;   Type 1 Diabetes;   Unclassified IAD Knee and/or Hip Arthritis, Muscular Dystrophy
Interventions: Other: 1: AID groups;   Other: 2: Control groups
32 Terminated HL2351 CAPS Phase II Study
Condition: Cryopyrin‑Associated Periodic Syndromes (CAPS)
Intervention: Drug: HL2351
33 Completed Clinical Outcomes and Safety: A Registry Study of Ilaris (Canakinumab) Patients
Conditions: Cryopyrin-associated Periodic Syndromes (CAPS);   Familial Cold Autoinflam Syn (FCAS);   Muckle-wells Syn (MWS);   Neonatal Onset Multisystem Inflam Disease (NOMID)
Intervention:
34 Completed The Safety and Efficacy of Canakinumab in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada
Condition: Cryopyrin Associated Periodic Syndrome
Intervention: Drug: canakinumab (company code: ACZ885D)
35 Terminated Canakinumab to Treat Neonatal-Onset Multisystem Inflammatory Disease
Conditions: NOMID;   CINCA Syndrome
Intervention: Drug: Canakinumab
36 Completed
Has Results
Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease
Conditions: Cryopyrin-associated Periodic Syndromes;   Familial Cold Autoinflammatory Syndrome;   Muckle-Wells Syndrome;   Neonatal Onset Multisystem Inflammatory Disease
Intervention: Biological: ACZ885
37 Completed
Has Results
Efficacy, Safety and Tolerability of ACZ885 in Pediatric Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease
Conditions: Cryopyrin-associated Periodic Syndromes;   Familial Cold Autoinflammatory Syndrome;   Muckle-Wells Syndrome;   Neonatal Onset Multisystem Inflammatory Disease
Intervention: Drug: ACZ885
38 Completed Safety and Tolerability of Rilonacept in Muckle-Wells Syndrome (MWS) or Schnitzler Syndrome (SchS)
Conditions: Muckle-Wells Syndrome;   Schnitzler Syndrome
Intervention: Drug: rilonacept
39 Completed Efficacy and Safety Study of Canakinumab Administered for 6 Months (24 Weeks) in Japanese Patients With Cryopyrin-associated Periodic Syndromes Followed by an Extension Phase
Conditions: Cryopyrin-associated Periodic Syndromes;   Familial Cold Autoinflammatory Syndrome;   Muckle-Wells Syndrome;   Neonatal Onset Multisystem Inflammatory Disease
Intervention: Drug: canakinumab
40 Completed
Has Results
Efficacy and Safety of ACZ885 in Patients With the Following Cryopyrin-associated Periodic Syndromes: Familial Cold Autoinflammatory Syndrome, Muckle-Wells Syndrome, or Neonatal Onset Multisystem Inflammatory Disease
Conditions: Cryopyrin-Associated Periodic Syndromes;   Familial Cold Autoinflammatory Syndrome;   Muckle Wells Syndrome;   Neonatal Onset Multisystem Inflammatory Disease
Intervention: Drug: Canakinumab (ACZ885)

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.